NBMolecules® SurfLink® technology has been developed over a period of 12 years by a multidisciplinary team from a number of renowned academic institutions including the University of Geneva (‘UniGe’), Ecole Polytechnique Fédérale de Lausanne (‘EPFL’), the University of Zürich and the University of Bern. This collaboration has given rise to a highly sophisticated surface treatment technology which offers a range of benefits not found in any other single surface treatment.
NBMolecules® SurfLink® technology is protected by patents owned by the UniGe and EPFL. According to a license agreement entered into with UniGe and EPFL, the university spin-off company NBMolecules®, established in 2002, owns the worldwide exclusive right to full and unrestricted use, development and exploitation of the technology.
In 2008 NBMolecules® established new laboratories and an office in Canton de Vaud, Switzerland. A small core team manages the company's day to day business. Over 65 contracts with research institutions and other external service providers have been established, and the company continues to grow.
Proof of concept – in vitro studies
Company founded: Spin-off EPFL and University of Geneva
Verification in small animal study
ISO 13485 production
Verification in large animal study
- 2008 (ongoing)
Validation in humans
- 2011 and 2013
CE-mark for two SurfLink® products
Technology Innovation Leadership Award by Frost & Sullivan
SurfLink® Dental kit presented at the European Association of Osseointegration conference in Rome
MIS® Implants Technologies and NBMolecules® conclude a License and Supply Agreement for use of the novel technology SurfLink® for treatment of MIS dental implants.
MIS and NBM presented the 'B+ surface' at MIS global conference in Barcelona. See the video at youtube.